Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-06-20 07:14 CEST (UTC+2h)

Enlighten me please [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-09-06 22:52  - Posting: # 17788
Views: 1,630

Hi Jag,

» I don't get it. The message has always been (or almost always been) to show BE for parent if it can be accurately quantified since it is the one that gets absorbed. Someone was :party: when the document was written?

I agree this is unusual. I don't know if they were partying too hard when they wrote this guideline but I can easily imagine there is a compromise of sorts involved here; perhaps someone from another FDA office (DBRUP?) wasn't convinced or was inexperienced with BE and used intuition instead of reason? Sometimes these guidelines, even though they are issued by OGD, involve a ton of inter-division compromises. I am sure that unless you find a really good reason buried in the material on the originator available via FOI the reason is going to be very hard to identify. :-|

We all have to be sheep in this situation, I guess.:-):-)

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,395 posts in 3,909 threads, 1,174 registered users;
online 33 (0 registered, 33 guests [including 16 identified bots]).

The analysis of variance is not a mathematical theorem,
but rather a convenient method of arranging the arithmetic.    R.A. Fisher

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed